THE TALK: Breast Cancer

home / the-talk / the-talk-breast-cancer

Experts in breast oncology gather for a discussion on important datasets in breast cancer recently presented at the ESMO 2021 Virtual Meeting.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.

Updates in HER2+ Breast Cancer from ESMO 2021

EP. 1: Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Interesting Trials in HER2+ Breast Cancer

EP. 2: Interesting Trials in HER2+ Breast Cancer

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

EP. 3: Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

ESMO 2021: Updates in Triple Negative Breast Cancer

EP. 4: ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.